Pavnit Kukreja
AbbVie (United States)(US)
Publications by Year
Research Areas
Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Restless Legs Syndrome Research, Autism Spectrum Disorder Research, Botulinum Toxin and Related Neurological Disorders
Most-Cited Works
- → The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review(2021)85 cited
- → Use of Social Media by Pharmacy Preceptors(2011)71 cited
- → Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications(2021)54 cited
- → Application of the ‘5-2-1’ Screening Criteria in Advanced Parkinson’s Disease: Interim Analysis of DUOGLOBE(2020)49 cited
- → Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety(2019)41 cited
- → DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease(2021)39 cited
- → Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States(2019)37 cited
- → Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results(2023)33 cited
- → Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance(2024)31 cited
- → Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa(2020)18 cited